6 Amendments of Francisco de Paula GAMBUS MILLET related to 2016/2057(INI)
Amendment 14 #
Motion for a resolution
Citation 5 a (new)
Citation 5 a (new)
- having regard to Decision No 1082/2013/EU of the European Parliament and of the Council of 22 October 2013 on serious cross-border threats to health and repealing Decision No 2119/98/EC,1 a __________________ 1a http://ec.europa.eu/health/preparedness_r esponse/docs/decision_serious_crossborde r_threats_22102013_es.pdf
Amendment 30 #
Motion for a resolution
Citation 6 a (new)
Citation 6 a (new)
- having regard to the joint procurement agreement approved by the Commission on 10 April 20141a, __________________ 1a http://ec.europa.eu/health/preparedness_r esponse/docs/jpa_agreement_medicalcou ntermeasures_en.pdf
Amendment 125 #
Motion for a resolution
Recital G a (new)
Recital G a (new)
Ga. whereas the Commission can use the joint procurement agreement on drugs, now signed by 20 Member States, to improve access to innovative medicines in more favourable conditions, and whereas that step will bring down the final cost for patients;
Amendment 249 #
Motion for a resolution
Paragraph 7 a (new)
Paragraph 7 a (new)
7a. Calls on the Commission to set out a clear definition on added value drugs, as taking that step could result in an increase in R&D investment in Europe;
Amendment 256 #
Motion for a resolution
Paragraph 7 b (new)
Paragraph 7 b (new)
7b. Emphasises that medicinal product innovation, in both molecules and simplification to improve adherence, may boost the public finances of European public health systems;
Amendment 353 #
Motion for a resolution
Paragraph 16 a (new)
Paragraph 16 a (new)
16a. Calls on the Commission to study the coordination of drug procurement among the Member States that have signed the joint procurement agreement, particularly for diseases such as hepatitis C, Crimean–Congo haemorrhagic fever and enteroviruses;